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Abstract
The National Vector Borne Disease Control Programme (NVBDCP) of the Ministry of Health,
Government of India is reporting about 2 million parasite positive cases each year, although case
incidence is 30-fold or more under-estimated. Forty five to fifty percent of Plasmodium infections
are caused by Plasmodium falciparum, the killer parasite. Anti-malaria drug policy (2007) of the
NVBDC recommends chloroquine (CQ) as the first line of drug for the treatment of all malarias.
In a Primary Health Centre (PHC) reporting 10% or more cases of CQ resistance in P. falciparum,
ACT blister pack is recommended and, so far, the policy has been adopted in 261 PHCs of 71
districts. The NVBDCP still depends on CQ to combat malaria and, as a result, P. falciparum has
taken deep roots in malaria-endemic regions, causing unacceptable levels of morbidity and
mortality. This policy was a subject of criticism in recent Nature and Lancet articles questioning the
World Bank's decision to supply CQ to the NVBDCP. Continuation of an outdated drug in the
treatment of P. falciparum is counterproductive in fighting drug resistant malaria and in the
containment of P. falciparum. Switchover to Artemisinin-based Combination Therapy (ACT) in the
treatment of all P. falciparum cases, ban on artemisinin monotherapy and effective vector control
(treated nets/efficient insecticide spraying) would be a rational approach to malaria control in India.
Background
The National Vector Borne Disease Control Programme
(NVBDCP) is reporting about 2 million parasite positive
cases a year, 50% of these Plasmodium falciparum. The
WHO estimates 100 million cases in the South East Asian
Region, 70% of these occur in India [1,2]. Independent
studies by the Indian Council of Medical Research have
unequivocally established that malaria incidence is
hugely under-estimated [3-6]. Health is the state's respon-
sibility, therefore, malaria control is carried out by the
states, under the overall guidance of the NVBDCP. To
monitor the impact of interventions surveillance is organ-
ized to detect malaria cases by examining fever cases in the
entire country. In rural areas, blood smears are collected at
fortnightly intervals by multi-purpose workers i.e.
through Active Case Detection (ACD) and also collected
at the Primary Health Centres (PHCs) i.e. Passive Case
Detection (PCD). In urban areas, PCD is carried out at the
malaria clinics. The blood smears are examined in the lab-
oratory for parasite identification and results are used for
follow-up action. Cases found positive are given radical
treatment, as per the policy of the NVBDCP. This data is
used in calculating epidemiological indices at the various
levels of health services. PHCs reporting cases of drug fail-
ure are referred to the drug monitoring teams for further
investigation on drug sensitivity in P. falciparum. If 25%
(now reduced to 10%) of the cases tested show resistance
to CQ, the drug policy is changed for the second line of
drug. Thirteen NVBDCP teams routinely monitor P. falci-
parum  drug sensitivity in the country. These teams are
located in various regions so as to cover the entire country.
P. falciparum monitoring for drug sensitivity is done using
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the World Health Organization (WHO) methodology of
in vivo (28-day) test procedure for determining the status
of resistance to CQ and other antimalarial drugs in P. fal-
ciparum. Malaria Drug Policy (2007) of the NVBDCP pro-
vides  inter alia the following treatment guidelines
countrywide [7].
1. All fever cases should preferably be investigated for
malaria by microscopy or Rapid Detection Test (RDT).
2. The first line of treatment is chloroquine and the sec-
ond line is ACT (artesunate+sulphadoxine/pyrimeth-
amine) combination in case resistant to these
formulations and to treat severe and complicated malaria,
quinine will be the drug of choice.
3. Microscopically positive P. falciparum cases should be
treated with chloroquine in therapeutic dose of 25 mg/kg
body weight over three days and a single dose of pri-
maquine 0,75 mg/kg body weight on the first day. The
practice is to be followed at all levels including Voluntary
Health Workers (VHWs) like Drug Distribution Centres
(DDCs)/Fever Treatment Depots(FTDs)/Accredited Social
Health Activist (ASHA) as well.
The antimalarial drug policy states that all Plasmodium
vivax cases, undiagnosed fever cases, and clinical malaria
cases should be treated with chloroquine in full therapeu-
tic doses. ACT (artesunate+sulphadoxine/pyrimeth-
amine) is the first line of antimalarial drug for treatment
of P. falciparum in chloroquine resistant areas. Chloro-
quine, therefore, remains the main drug for the treatment
of all malarias in India except in PHCs with 10% or more
cases found resistant to it. The objective of this paper is to
highlight the realistic and evidence-based malaria situa-
tion in the country, and how the changes in drug policy
and efficient vector control can wipe out malaria, thus
bringing out the importance of the WHO recommenda-
tion of a switch over to artemisinin-based fixed-dose com-
bination therapy (ACT) to treat all P. falciparum cases
(sensitive or resistant to CQ/SP).
Discussion
Studies on re-emergence of malaria revealed countrywide
presence and spread of P. falciparum e.g. P. falciparum is
found in all states and union territories except Lakshad-
weep Island (Malaria situation 2002–2006, NVBDCP). It
may be noted that P. falciparum occurrence is highly une-
ven in time and space [8,9]. Furthermore, the NVBDCP is
reporting malaria epidemics in five or six states each year,
and frequent focal outbreaks [10]. In some parts of the
country, malaria epidemics cover two or more districts,
dominated by P. falciparum [11-14]. Currently an epi-
demic of malaria is raging in Assam, a region more fre-
quently visited by annual exacerbations [15,16]. The
country-wide presence of P. falciparum is facilitated by
inter- and intra-state population movement, particularly
for civil works, agriculture, rail road construction, rural
urban migration; thus providing opportunities for the
mutant strains to disseminate across district and state
boundaries [17-19].
It is important to highlight the resilience of P. falciparum
in India. During the early years of malaria resurgence [20],
a focus of P. falciparum and detection of CQ resistant foci
in Karbi-Anglong district in Assam [21] in the north-east-
ern states required steps for its containment and preven-
tion of its spread to the mainland. Therefore, a special
drive was launched under the P. falciparum Containment
Programme (PfCP), financed by the Swedish Interna-
tional Development Agency (SIDA). PfCP was first
launched in 1978 in 18 high P. falciparum districts in the
north-eastern states, gradually extended to 55 districts
(311 PHCs in 14 states) and in 1982 to 110 districts (1410
PHCs in 18 states). Despite of PfCP operations that heav-
ily depended on Dichloro-Diphenyl-Trichloroethane
(DDT) and Chloroquine (CQ), P. falciparum occupied
larger territories and covered the entire county's transmis-
sion belts and remained firm. The purpose and the strat-
egy of PfCP was defeated and PfCP was terminated in
1988 [22]. Epidemiological investigations revealed that P.
falciparum was replacing P. vivax in central India [23]. It is
noteworthy to mention that decadal P. falciparum rise has
been substantial, an increase of 120% since the first resur-
gence decade (1971–80). P. falciparum is rising slowly but
steadily [24] over these decades as shown in Figure 1.
Malaria epidemiology and its control are complicated by
poverty as it is a dominant disease in poverty stricken soci-
eties. For example, Indian states with population exceed-
ing the national average of 26.1% population below
poverty line (BPL) contributed 88% P. falciparum in 2000
[25]. Addressing the plenary session of United Nations
Conference on Human Environment at Stockholm,14
June 1972, the former Prime Minister of India Smt. Indira
Gandhi said "Are not poverty and need the greatest pollut-
ers? [26] Poverty alleviation is on the national and United
Nations agenda. How to fight poverty which is at the roots
of all ills? Certainly malaria control is an important tool
to alleviate human suffering caused by poverty and ill
health. Therefore, priorities in malaria control should
remain high, national and international bodies should
work in tandem to eradicate this age old "King of all Dis-
eases".
Plasmodium falciparum monitoring for drug sensitivity is
conducted by thirteen NVBDCP teams. Monitoring is
done on the line of WHO methodology of in vivo (28-day)
standard techniques for determination of resistance in P
falciparum to CQ and other antimalarials. India is a vastMalaria Journal 2007, 6:105 http://www.malariajournal.com/content/6/1/105
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country, so it is difficult to generalize. However, between
1978 and June 2001, a total of 15,069 P. falciparum cases
in 178 districts of 28 states and union territories have
been completed. Of these 3,965 (26.3%) were sensitive to
CQ; 7,661 (50.8) were S/RI; 2,142 RI resistant; 752 RII
resistant (5%) and 549 (3.6%) RIII resistant to CQ [27].
In 2004, the P. falciparum monitoring teams collected
45,966 blood smears, of which 4,756 were positive for
malaria and 3,850 for P. falciparum (80.95%). Results
based on CQ sensitivity of 209 samples, showed Adequate
Clinical and Parasitological Response (ACPR) 98
(47.9%), Early Treatment Failure (ETF) 27 (12.9%) and
Late Treatment Failure (LTF) 84 (40.2%). Drug resistance
to CQ is presenting countrywide, although proportion of
resistant strains varies greatly [28-33]. Already the Pfcrt
K76T mutation, an important determinant of CQ resist-
ance, is present in >95% of P. falciparum isolates [34]. In
addition to these clear indicators of resistance in the para-
site populations, there are important changes in disease
outcomes. For example, in patients with P. falciparum
infections, acute renal and multi-organ failures have
almost doubled in the last 5–7 years. Although it is not
possible to attribute this directly to the decreasing efficacy
of CQ, but it may be an important factor, as it has been in
malaria-related deaths in African children [35]. The dete-
riorating trends in P. falciparum demands urgent radical
changes in antimalarial drug policy. ACT is currently used
in 261 PHCs (71 districts) as against approximately
14,000 malaria endemic PHCs. The process of adoption
to ACT is painfully slow and may take a long time, until
then CQ remains the first line drug in India. In 2006 a
series of articles in The Lancet [36-38] and Nature [39]
concerned funding of antimalaria drugs by the World
Bank. The Lancet paper criticized the World Bank for
funding the purchase of CQ by the Indian government.
There is substantial evidence that CQ is no longer effective
against P. falciparum in many areas of India, and under
those circumstances the purchase of CQ supports a dan-
gerous public health practice. One response to the criti-
cism was that CQ is used in India only to combat P. vivax,
a species against which it is mostly still effective. This
statement contradicts the drug policy of the NVBDCP
which recommends the use of CQ to treat all malaria
cases, including P. falciparum, the more lethal pathogen.
It may be underscored that malaria situation in India is
worsening due to ineffective vector control largely the
result of DDT spraying [40] and the poor choice of anti-
malarials, for example India's CQ consumption in 1976
was 61 metric tons (mt) to treat 6.45 million cases (the
highest since resurgence) and, in 2005, cases have been
reduced by 70%, but CQ consumption has increased ten
times [41]. Table 1 illustrates one example among many,
of the impact of inefficient spraying and increasing
dependence on CQ. In Betul district, Madhya Pradesh, a
malaria epidemic was building-up due to inefficient and
inadequate DDT spraying and the decreasing effectiveness
of CQ. Thus, the CQ use increased enormously with no
signs of epidemic abatement. Several measures were
required to finally control the epidemic: a switch from
DDT to synthetic pyrethroid (SP) indoor residual spray-
ing, introduction of larvivorous Gambusia (Gambusia
affinis) and Guppy (Poecilia reticulata) fishes, and on-spot
diagnosis to cover all households was initiated. Then with
correct diagnosis, only P. vivax was treated with CQ; P. fal-
ciparum was treated with sulfadoxine-pyrimethamine (P.
falciparum was susceptible to it). With these changes, the
district was nearly malaria free by 2005 [42].
The WHO recommends fixed dose artemisinin combina-
tion therapy for P. falciparum [43]. In light of the clear evi-
dence for CQ-resistance in P. falciparum, and the
P. falciparum cases in India (1961–2004) Figure 1
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recommendation for using CQ as the treatment for all
malaria, not just P. vivax, the NVBDCP should respond to
the recommendation of the Lancet Viewpoint and aban-
don CQ, in favour of ACT. Indian states with high preva-
lence of P. falciparum have the problem of CQ resistance,
although the proportion remains undetermined. CQ and
sulphadoxine/pyrimethanine (SP) resistance is more pro-
nounced in the north-eastern states and Orissa. Multid-
rug-resistant strains abound on the international borders
with the Indian NE states [44-46]. Artesunate with SP
combination (blister pack) is now recommended in drug
resistant areas. In seven states in the northeastern region
of the country, ACT is being introduced in one district in
each state in the pilot phase. Further expansion would
depend on the experience gained in the districts in north-
eastern region. This switch over to ACT would take place
in 71 districts in the country (261 PHCs, but there are
approximately 14,000 high risk PHCs requiring ACT to
treat P. falciparum), with provision to expand this coverage
to adjacent PHCs reporting >10% CQ resistant P. falci-
parum. States have been advised to monitor the status of
drug resistance in the adjacent PHCs for the expansion of
ACT. PHCs lacking microscopic facility would be supplied
with rapid diagnostic test kits to detect P. falciparum. Fur-
thermore, artemisinin drugs are frequently used as mono-
therapy in the private sector, the racket of substandard
and fake drugs [47], private sector working in isolation,
government support to herbal drugs failing in scientific
scrutiny [48] and indiscretion in the use of artemisinin are
dangerous signals, and failure to address these problems
may endanger life of patients and accelerate resistance.
Thus the inertia may open the possibility of an epicenter
of drug resistant malaria in South East Asia. Finally, with-
holding correct malaria treatment for unfounded reasons,
lacking sound scientific basis and wise clinical judgment,
is both unethical and discriminatory. Malaria is predomi-
nantly the disease of the poor lacking health equity. This
inequity should be leveled by following correct drugs and
drug schedule to the needy and unprotected for a relent-
less war against malaria. Setting the house in order is a for-
midable challenge. Therefore, inter alia policy issues must
be addressed by the NVBDCP first and the foremost.
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